Ovarian Cancer pp 285-292 | Cite as

Expression of CSF-1 and Its Receptor CSF-1R in Non-Hematopoietic Neoplasms

  • Barry Kascinski
Part of the Cancer Treatment and Research book series (CTAR, volume 107)


In 1984, long before anyone had even conceived of the possibility of DNA microarray analyses of gene expression in histologic sections, we employed a rather cumbersome and laborious in situ hybridization analysis of cDNAs to tissue RNA in serial sections of ovarian, endometrial, and breast carcinomas (in which autoradiographic grains were counted and data calculated in terms of cDNA hybrids/square micron of tissue). Our purpose was to ascertain whether the levels of transcript expression of any of 20 genes under study correlated with tumor grade and clinical stage (which even in the year 2000 remain the best overall predictors of prognosis in patients with these three neoplasms). Out of over 20 genes studied, only the levels of the transcript of the fms oncogene, which had at that time recently been shown to encode the receptor for CSF-1 (CSF-1R) correlated strongly with both grade (p < 0.001) and stage (p < 0.04) and thus, indirectly, with clinical outcome [1].


Endometrial Carcinoma Endometrial Adenocarcinoma Anchorage Independent Growth Ovarian Carcinoma Patient Endometrial Cell Line 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kacinski BM, Carter D, Mitral K, Kohom EI, Bloodgood RS, Donahue J, Donofrio L, Edwards R, Schwartz PE, Chambers JT, Chambers SK. High Level Expression of FMS Proto-oncogene mRNA is Observed in Clinically Aggressive Human Endometrial Adenocarcinomas. Int J Radiat Oncol Biol Phys 1988; 15: 823–829.PubMedCrossRefGoogle Scholar
  2. 2.
    Stanley ER, Guilbert LJ. Methods for the purification, assay, characterization and target cell binding of a colony-stimulating factor, CSF-1 J. Immunol. Methods 1989; 42: 53–284.Google Scholar
  3. 3.
    Taylor GR, Reedijk M, Rothwell V., Rohrschneider L, Pawson T. The unique insert of cellular and viral fins protein kinase is indispensable for enzymatic and transforming activity. EMBO J 1989; 8: 2029–2037.PubMedGoogle Scholar
  4. 4.
    Kacinski BM, Stanley ER, Carter D, Chambers JT, Chambers SK, Kohorn EI, Schwartz PE. Circulating Levels of CSF-1 (M-CSF), a Lymphohematopoietic Cytokine, May Be a Useful Marker of Disease Status in Patients with Malignant Ovarian Neoplasms. Int J Radiat Oncol Biol Phys 1989; 17: 159–164.PubMedCrossRefGoogle Scholar
  5. 5.
    Kacinski BM, Carter D, Kohorn El, Mittal K, Bloodgood RS, Donahue J, Kramer CA, Fischer D, Edwards R, Chambers SK, Chambers JT, Schwartz PE. Oncogene Expression in vivo by Ovarian Adenocarcinomas and Mixed-mullerian Tumors. Yale J Biol Med 1989; 62: 379–392.PubMedGoogle Scholar
  6. 6.
    Kacinski BM, Bloodgood RS, Schwartz PE, Carter DC, Stanley ER. The macrophage colony stimulating factor CSF-1 is produced by human ovarian and endometrial adenocarcinoma-derived cell lines and is present at abnormally high levels in the plasma of ovarian carcinoma patients with active disease. Molecular Diagnostics of Human Cancer, Ca. Cells 7, Cold Spring Harbor Press, Cold Spring Harbor, NY, pp 333–337, 1989.Google Scholar
  7. 7.
    Tapley P, Kazlauskas A, Cooper JA, Rohrschneider LR. Macrophage colony stimulating factor induced tyrosine phosphorylation of c-fms protein expressed in FDC-P1 and Balb/c T3 cells. Mol Cell Biol 1990; 10: 2538–2558.Google Scholar
  8. 8.
    Kacinski BM, Carter D, Mittal K, Yee LD, Scata KA, Donofrio L, Chambers SK, Wang KI, Yang-Feng T, Rohrschneider LR, Rothwell V. Ovarian Adenocarcinomas Express fins-complementary Transcripts and Antigen, Often With Co-expression of CSF-l. Am J Pathol 1990; 137: 135–147.PubMedGoogle Scholar
  9. 9.
    Kacinski BM, Chambers SK, Stanley ER, Carter DC, Tseng P, Scata KA, Chang DHY, Pirro MH, Nguyen JT, Ariza A, Rohrschneider LR, Rothwell V. The Cytokine CSF-1 (M-CSF), Expressed by Endometrial Carcinomas in vivo and in vitro, May Also Be a Circulating Tumor Marker of Neoplastic Disease Activity in Endometrial Carcinoma Patients. Int J Radiat Oncol Biol Phys 1990; 19: 619–626.PubMedCrossRefGoogle Scholar
  10. 10.
    Kacinski BM, Chambers SK, Carter D, Filderman AE, Stanley ER. The Macrophage Colony Stimulating Factor CSF-1, an Auto-and Paracrine Tumor Cytokine, is also a Circulating “Tumor Marker” in Patients with Ovarian, Endometrial and Pulmonary Neoplasms. In: “The Physiological and Pathological Effects of Cytokines”, Dinarello, C.A., et al., eds., New York, Wiley-Liss, Prog Leuk Biol 10B: 393–400, 1990.Google Scholar
  11. 11.
    Tang R, Kacinski BM, Validire P, Beuvon F, Sastre X, Benoit P, de la Rochefordiere A, Mosseri V, Pouillart P, Scholl S. Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoieitic growth factor release by tumor cells? J Cell Biochem 1990; 44: 189–198.PubMedCrossRefGoogle Scholar
  12. 12.
    Kacinski BM, Scata KA, Carter D, Yee LD, Sapi E, King BL, Chambers SK, Jones MA, Pirro 3MH, Stanley ER, Rohrschneider LR. FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro. Oncogene 1991; 6: 941–952.PubMedGoogle Scholar
  13. 13.
    Filderman AE, Bruckner A, Kacinski BM, Deng N, Remold HG. Macrophage colony-stimulating factor (CSF-1) enhances invasiveness in CSF-1 receptor-positive carcinoma cell lines. Cancer Res 1992; 52 (13): 3661–3669.PubMedGoogle Scholar
  14. 14.
    Pellici G. Lauframcone I. Grignani F. McGlade J, Cavallo F. Forni G, Nicolletti I, Grignani F Pawson T, Pellici PG. A novel transforming protein SHC with an SH2 domain is implicated in mitogenic signal transduction. Cell 1992; 70: 93–104.CrossRefGoogle Scholar
  15. 15.
    Price FV, Chambers SK, Chambers JT, Carcangiu ML, Schwartz PE, Kohom EI, Stanley ER, Kacinski BM. Colony-stimulating factor-1 in primary ascites of ovarian cancer is a significant predictor of survival. Am J Obstet Gynecol 1993; 168: 520–527.PubMedGoogle Scholar
  16. 16.
    Courtneidge SA, Dhand R, Pilat D, Twalmley GM, Waterfield MD, Roussel MD. Activation of Src kinases by CSF-1 and their association with its receptor. EMBO J 1993; 12: 943–950.PubMedGoogle Scholar
  17. 17.
    Bauknecht T, Kiechle-Schwarz M, duBois A, Wölfle J, Kacinski BM. Expression of transcripts for CSF-1 and for the “macrophage” and “epithelial” isoforms of the CSF-1R transcripts in human ovarian carcinomas. Cancer Detect Prey 1994; 18: 231–239.Google Scholar
  18. 18.
    Chambers SK, Wang Y, Gilmore-Hebert M, Kacinski BM. Post-transcriptional regulation of c-fms proto-oncogene expression by dexamethasone and of CSF-1 in human breast carcinomas in vitro. Steroids 1994; 59: 514–522.PubMedCrossRefGoogle Scholar
  19. 19.
    Kommoss F, Wölfle J, Bauknecht T, Pfisterer J, Kiechle-Schwartz M, Pfleiderer A, Sauerbrei W, Kiehl R, Kacinski BM. Co-expression of M-CSF transcripts and protein, FMS (M-CSF receptor) transcripts and protein, and steroid receptor content in adenocarcinomas of the ovary. J Pathol 1994; 174: 111–119.PubMedCrossRefGoogle Scholar
  20. 20.
    Carlberg K. Rohrscheider L. The effect of inactivating mutations on dimerization, tyrosine phosphorylation, and internalization of the macrophage colony stimulating factor. Mol Cell Biol 1994; 5: 81–95.Google Scholar
  21. 21.
    Sapi E, Flick MB, Gilmore-Hebert M, Rodov S, Kacinski BM. Transcriptional regulation of the c-fms (CSF-lr) proto-oncogene in human breast carcinoma cells by glucocorticoids. Oncogene 1995; 10: 529–542.PubMedGoogle Scholar
  22. 22.
    Troilaris S. Smola U, Chang J-H, Parsons SJ, Niemann H. Tamura T. Tyrosine 807 of the vfms oncogene product controls cell morphology and association with pl20rasGAP. J Virol 1995; 69: 6010–6020.Google Scholar
  23. 23.
    Chambers SK, Wang Y, Gertz RE, Kacinski BM. Macrophage colony stimulating factor mediates invasion of ovarian cancer cells through urokinase. Cancer Res 1995; 55: 1578–1585.PubMedGoogle Scholar
  24. 24.
    Hakala A, Kacinski BM, Stanley ER, Kohorn E, Puistola U, Risteli J, Risteli L, Tomas C, Kauppila A. Macrophage-colony stimulating factor 1, a clinically useful tumor marker in endometrial adenocarcinoma; comparison with CA-125 and aminoterminal propeptide of type III procollagen. Am J Obstet Gynecol 1995; 173: 112–119.PubMedCrossRefGoogle Scholar
  25. 25.
    Sapi E, Flick MB, Rodov S, Gilmore-Hebert M, Kelley M, Rockwell S, Kacinski BM. Independent regulation of invasion and anchorage-independent growth by different autophosphorylation sites of the macrophage colony-stimulating factor 1 receptor. Cancer Res 1996; 56: 5704–12.PubMedGoogle Scholar
  26. 26.
    van der Geer, Hunter T. Mutation of Tyr697, a GRB2 binding site and TYR-721, a PI-3 kinase binding site, abrogates signal transduction by the murine CSF-1 receptor expressed in Rat-2 fibroblasts. EMBO J 1996; 12: 5161–5172.Google Scholar
  27. 27.
    Hamilton J.A. CSF-I signal transduction. J. Leukocyte Biology 1997; 62: 145–155.Google Scholar
  28. 28.
    Flick MB, Sapi E, Perrotta L, Maher MG, Halaban R, Carter D, Kacinski BM. Recognition of activated CSF-1 receptor in breast carcinomas by a tyrosine 723 phosphospecific antibody. Oncogene 1997; 14: 2553–2561.PubMedCrossRefGoogle Scholar
  29. 29.
    Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML. Overexpression of epithelial CSF-1 and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer; contrasted to a protective effect of stromal CSF-1. Clin Cancer Res 1997; 3: 999–1007.PubMedGoogle Scholar
  30. 30.
    Maher MG, Sapi E, Turner B, Gumbs A, Perrotta PL, Carter D, Kacinski BM, Haffty B. CSF1R expression correlates with local recurrence in breast cancer patients. Clinical Cancer Research 1998; 4: 1851–1856.PubMedGoogle Scholar
  31. 31.
    Sapi E, Flick MB, Rodov S, Carter D, Kacinski BM. Expression of CSF-1 and CSF-1 receptor by normal lactating mammary epithelial cell. J Soc Gynecol Invest 1998; 5: 94–101.CrossRefGoogle Scholar
  32. 32.
    Sapi E, Flick MB, Rodov S, Kacinski BM. Ets-2 transdominant mutant abolishes anchorage-independent growth and CSF-1-stimulated invasion by BT20 breast carcinoma cells. Cancer Res 1998; 58: 1027–1033.PubMedGoogle Scholar
  33. 33.
    Kacinski BM, Rodov S, Sapi E. Signal Transduction Pathways Regulated by CSF-I Receptors Modulate the In Vitro Radiosensitivity of Mammary Epithelial Cells. Int. J. Radiation Oncology Biol Phys 1999; 45 (4): 969–973.CrossRefGoogle Scholar
  34. 34.
    Sapi E, Flick M, Tartaro K, Kim S, Rakhlin Y, Rodov S, Kacinski BM. Effect of All-transRetinoic Acid on c-fms Proto-oncogene [Colony-stimulating Factor 1 (CSF-1) Receptor] Expression and CSF-1-induced Invasion and Anchorage-independent Growth of Human Breast Carcinoma Cells. Cancer Research 1999; 59: 5578–5585.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Barry Kascinski
    • 1
  1. 1.Department of Therapeutic RadiologyYale University School of MedicineNew HavenUSA

Personalised recommendations